Amgen AMGN announced that the FDA has approved its KRAS inhibitor, Lumakras (sotorasib), in combination with its anti-EGFR antibody, Vectibix (panitumumab), for treating KRAS G12C-mutated ...

Meanwhile, Amgen is also running a series of phase 1b studies of Lumakras in first-line KRAS G12C-mutated NSCLC in combination with other drugs, such as MEK, EGFR or checkpoint inhibitors, as well ...

That said, which KRAS mutations are seen in around 90% of pancreatic cancer patients, only 1% to 2% are KRAS G12C, so both Amgen and Mirati could be chasing a small patient population with the new ...

Amgen (NasdaqGS:AMGN)'s recent affirmation of a $2.38 per share dividend for Q2 2025 could reflect investor confidence and ...

NEW YORK – Alterome Therapeutics said on Monday it has started treating patients with KRAS-mutant advanced solid tumors with its KRAS inhibitor ALTA3263 in a Phase I trial.

Amgen's free cash flow soared to $10.4 billion last year from $7.4 billion in 2023. The company also won U.S. Food and Drug Administration approval for Lumakras last month as a treatment for KRAS ...

In early February, Amgen released financial results for the 4th quarter of 2024, which I was eagerly awaiting. In addition to demonstrating efficacy in the treatment of nasal polyps in Phase 3 ...

Drugmaker Amgen to invest $200 million in India site, CEO says U.S. drugmaker Amgen will invest about $200 million this year in its new technology centre in southern India, with further ...

The presence of primary resistance and KRAS G12C co-mutations may explain limited single-agent efficacy of marketed KRAS inhibitors, a recent study suggests.